

# ASX Release

---

## **SUDA ANNOUNCES STRONG FY2017 REVENUE GROWTH FOR WESTCOAST SUBSIDIARY**

**PERTH, AUSTRALIA – 24 July 2017:** SUDA LTD (ASX: SUD), a leader in oro-mucosal drug delivery, today announced that its wholly owned subsidiary Westcoast Surgical & Medical Supplies (“Westcoast”) reported revenue of \$6.7 million for the 2017 financial year, an increase of 16 per cent compared to the previous year.

During the period, Westcoast was awarded several new contracts. These included the supply of medical products to oil rigs, ships, custom vessels and floatels.

The anticipated expansion of these contracts should continue to drive growth at Westcoast. In addition, Westcoast has submitted several large tenders to supply companies in the resources sector as well as infrastructure projects and decompression vessels. With these additional opportunities, Westcoast is expected to maintain its double-digit revenue growth in FY2018.

Mr Stephen Carter, SUDA’s Managing Director & CEO, commented: “We are delighted by the revenue and profit growth at our subsidiary, Westcoast. The new supply contracts for the offshore resource sector are a higher margin business than Westcoast’s traditional activities. Westcoast has continued to expand these revenue streams and anticipates several new contracts in FY2018 based on its strong track record of customer service. With positive cash flow and strong revenue growth trajectory, Westcoast is working to deliver significant value to SUDA’s shareholders.”



**Further information:**  
**STEPHEN CARTER**  
**CHIEF EXECUTIVE OFFICER / MANAGING DIRECTOR**  
**SUDA LTD**  
Tel: +61 8 6142 5555  
[sjcarter@sudaltd.com.au](mailto:sjcarter@sudaltd.com.au)

## **NOTES TO EDITORS:**

### **About SUDA LTD**

SUDA LTD (ASX: SUD) is a drug delivery company focused on oro-mucosal administration, headquartered in Perth, Western Australia. The Company is developing low-risk oral sprays using its OroMist® technology to reformulate existing pharmaceuticals. The many potential benefits of administering drugs through the oral mucosa (i.e.: cheeks, tongue, gums and palate) include ease of use, lower dosage, reduced side effects and faster response time. SUDA's product pipeline includes ZolpiMist™, a first-in-class oral spray of zolpidem for insomnia. ZolpiMist is marketed in the USA and SUDA has rights to the product outside of the US and Canada. SUDA's most advanced development-stage product, ArTiMist®, is a novel sublingual malaria treatment for children. In a Phase III trial, ArTiMist was shown to be superior to intravenous quinine. Other products in development include oral sprays for the treatment of migraine headache, chemotherapy-induced nausea and vomiting, erectile dysfunction and pre-procedural anxiety. For more information, visit [www.sudaltd.com.au](http://www.sudaltd.com.au)

### **About Westcoast Surgical & Medical Supplies**

Westcoast Surgical & Medical Supplies (Westcoast) is a sales and logistics organisation distributing healthcare consumables and capital equipment, primarily in the West Australian marketplace. It was established as a family business in 1995. SUDA Ltd acquired the business in 2006. Westcoast operates as a distributor in a standard industry model and services the hospital, aged care, resources and diverse allied health areas amongst others. For more information, visit [www.westcoastsurgical.com.au](http://www.westcoastsurgical.com.au)